WO2024246841 - MARIBAVIR COMPOSITIONS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/246841
Publication Date
05.12.2024
International Application No.
PCT/IB2024/055318
International Filing Date
30.05.2024
Title **
[English]
MARIBAVIR COMPOSITIONS AND USES THEREOF
[French]
COMPOSITIONS DE MARIBAVIR ET LEURS UTILISATIONS
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
SUEDA, Katsuhiko
Priority Data
63/470,161
31.05.2023
US
63/525,228
06.07.2023
US
63/633,277
12.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4262 | |
| EPO | Filing, Examination, Granting | 55660 | |
| Japan | Filing, Examination, Granting | 3914 | |
| South Korea | Filing, Examination, Granting | 5721 | |
| USA | Filing, Examination, Granting | 19940 |
Total:
89,497
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides novel methods and compositions for using maribavir in the treatment of pediatric and adolescent patient populations. The present disclosure also provides compositions of maribavir in the form of a powder for oral suspension, which are useful for patients with difficulty swallowing pills, including pediatric and adolescent patient populations.[French]
La présente divulgation concerne de nouveaux procédés et compositions pour utiliser du maribavir dans le traitement de populations de patients pédiatriques et adolescents. La présente divulgation concerne également des compositions de maribavir sous la forme d'une poudre pour suspension orale, qui sont utiles pour des patients présentant des difficultés à avaler des pilules, notamment des populations de patients pédiatriques et adolescents.